Brainomix

medical devices

About

Brainomix is a medical software company founded in 2010 as a spin-out from the University of Oxford. The company specializes in AI-powered imaging biomarkers that enhance precision medicine and improve treatment decisions for patients worldwide. Its flagship product, Brainomix 360 Stroke, is an AI imaging platform that automates validated imaging biomarkers to support clinicians in acute stroke care, enabling faster and more confident decision-making. Brainomix focuses on providing advanced imaging solutions for healthcare providers, hospitals, and healthcare systems globally. The company collaborates with pharmaceutical companies to support clinical trials and therapeutic development by offering imaging biomarkers. Under the leadership of CEO Dr. Michalis Papadakis, Brainomix has achieved significant growth, received regulatory approvals, including FDA clearance in 2023, and continues to expand its AI technology into other therapeutic areas.

Technologies

SalesforceRoute 53Amazon SESOutlookMicrosoft Azure HostingAtlassian CloudMicrosoft AzurereCAPTCHAGoogle Tag ManagerHotjarMicrosoft-IISBootstrap FrameworkTypekitASP.NETMobile FriendlyShutterstockVimeoGoogle PlayYouTubeWordPress.org

Keywords

healthcareaistrokeinterstitial lung diseasemedicalmedical deviceshealth caremedical equipment manufacturingstroke treatment optimizationsolid tumor imagingai-powered medical devicesai clinical solutionspredictive analyticsai-based treatment decisionsservicesai for medical workflowsbusiness intelligenceai in healthcare systemsai medical technologyai for neurological disordersai biomarkers for lung fibrosislung fibrosis assessmentai for healthcare providersautomated stroke detectionb2bhealthtech ai solutionsai in stroke managementai for personalized treatmentai for healthcare innovationstroke diagnosis software

Location

West Way, Oxford, England, United Kingdom, OX2 0PH

Related Companies

Companies in the same industry